Researchers reported a number of important findings in sarcoma treatment at the 2019 Annual Meeting of the American Society of Clinical Oncology:

Adding targeted therapy to chemotherapy did not increase survival in soft-tissue sarcoma

The phase III ANNOUNCE trial studied the combination of the chemotherapy doxorubicin and the targeted therapy olaratumab in treatment of advanced soft-tissue sarcoma, compared to treatment with doxorubicin alone.

What Patients Need to Know

The results of ANNOUNCE found that adding olaratumab to chemotherapy did not increase survival. In April 2019, olaratumab was withdrawn from the market.

Standard versus tailored chemotherapy evaluated in treatment of soft-tissue sarcoma

A randomized phase III clinical trial is evaluating the treatment of localized high-risk soft-tissue sarcoma (STS) with the standard chemotherapy (epirubicin plus ifosfamide) compared to chemotherapy tailored to the specific type of STS.

What Patients Need to Know

This trial is designed to verify the hypothesis that a tailored approach is associated with an overall 30 percent reduction in the risk of relapse.

Adding pre-operative radiotherapy to surgery alone did not show benefit in retroperitoneal sarcoma

STRASS, an international phase III randomized trial, evaluated the effectiveness of pre-operative radiotherapy plus surgery compared with surgery alone in the treatment of retroperitoneal (abdominal) sarcoma.

What Patients Need to Know

The results of the trial failed to show a benefit of pre-operative radiotherapy in the treatment of retroperitoneal sarcoma. However, an exploratory analysis indicated that pre-operative radiotherapy may benefit patients being treated for liposarcoma, a subtype of retroperitoneal sarcoma.